GlaxoSmithKline, Ranbaxy settle Valtrex patent dispute

Share this article:

Generics drug firm Ranbaxy Laboratories said it has reached an agreement with GlaxoSmithKline resulting in a dismissal of US patent litigation regarding Glaxo's herpes pill Valtrex (valacyclovir hydrochloride).

Under the agreement, Ranbaxy will be allowed to introduce its generic version of Valtrex in the US in late 2009 and will have 180 days of sales product exclusivity.

In early February 2007, Ranbaxy received a final approval from the FDA to market and manufacture valacyclovir hydrochloride tablets.

Glaxo's Valtrex patent is set to expire in 2009 in the US and most of Europe. The drug was first introduced in 1995.

Total global sales of Valtrex were around $1.3 billion for 2006.

 

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.